Investment Summary

EW Healthcare Partners Invests In Xenex

On February 24, 2017, growth capital firm EW Healthcare Partners invested in medical products company Xenex

Investment Highlights
  • This is EW Healthcare Partners’ 23rd transaction in the Medical Products sector.
  • This is EW Healthcare Partners’ 47th transaction in the United States.
  • This is EW Healthcare Partners’ 2nd transaction in Texas.

Investment Summary
Date 2017-02-24
Target Xenex
Sector Medical Products
Investor(s) EW Healthcare Partners
Deal Type Venture

Target

Xenex

San Antonio, Texas, United States
Xenex is a manufacturer of LightStrike Germ-Zapping Robots. Xenex’s patented pulsed xenon Full Spectrum UV room disinfection system is a pesticidal device used for the advanced cleaning of healthcare facilities. Xenex’s mission is to save lives and reduce suffering by eliminating the deadly microorganisms that cause hospital acquired infections (HAIs). Xenex was founded in 2008 and is based in San Antonio, Texas.

Search 201,292 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try For Free 7-Day Free Trial

Investor(S) 1

Investor

EW Healthcare Partners

Investor Investor Investor Investor Investor

Category Growth Capital Firm
Founded 1985
PE ASSETS 3.0B USD
Size Large
Type Sector Focused
DESCRIPTION

Essex Woodlands Health Ventures is a growth equity and venture capital specialist investment firm focused on opportunities across the healthcare sector. Specific areas of interest include biotechnology, pharmaceuticals, medical devices, and healthcare services/IT. Historically, Essex invested primarily in early and later-stage situations; however, today the firm also makes growth capital investments between $20 - $60 million in companies valued between $50 - $250 million, as well as private investments in public entities (PIPEs). Essex Woodlands was formed in 1985 and offices in Palo Alto, California; New York City; Houston, Texas; Shanghai and London.

DEAL STATS #
Overall 52 of 59
Sector (Medical Products) 23 of 24
Type (Venture) 32 of 32
State (Texas) 2 of 2
Country (United States) 47 of 50
Year (2017) 1 of 2
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2016-12-20 Cota

New York, New Jersey, United States

Cota, Inc. is a provider of health care informatics and precision analytics company that builds research-grade, real-world data to exponentially improve outcomes, reduce cost and ensure the right care for the right patient every time. Cota was founded in 2011 and is based in New York City.

Buy -
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2017-05-09 MedAvante

Hamilton, New Jersey, United States

MedAvante is a clinical science-driven data services company dedicated to maximizing signal detection in global clinical trials. With VirgilÔ, its electronic clinical outcome assessment (eCOA) platform, clinical research sponsors are able to maximize outcome data quality and increase operational efficiency for clinical trials across multiple therapeutic areas. MedAvante built the first electronic source (eSource) data platform and has conducted more than 687,000 assessments of 56,000 clinical trial subjects across 233,000 study visits. MedAvante’s eSource data has been accepted by both the Food and Drug Administration and the European Medicines Agency in successful regulatory submissions.

Sell -
Mergr

Product

Company

Legal